Veradermics, Incorporated - Asset Resilience Ratio
Veradermics, Incorporated (MANE) has an Asset Resilience Ratio of 55.79% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Veradermics, Incorporated to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Veradermics, Incorporated's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Veradermics, Incorporated assets under control.
Liquid Assets Composition Over Time
This chart breaks down Veradermics, Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Veradermics, Incorporated balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $222.38 Million | 55.79% |
| Total Liquid Assets | $222.38 Million | 55.79% |
Asset Resilience Insights
- Very High Liquidity: Veradermics, Incorporated maintains exceptional liquid asset reserves at 55.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Veradermics, Incorporated Industry Peers by Asset Resilience Ratio
Compare Veradermics, Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Veradermics, Incorporated (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Veradermics, Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 78.69% | $120.10 Million | $152.62 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $59.38 Million | -- |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more